As discussed above, targeting the RANK-RANKL axis using the RANKL inhibitor Denosumab offers a potential new avenue as a preventative treatment for breast cancer in women with germline BRCA1 mutations. The gene discussed is TNFRSF11A; the disease is breast cancer.